Tasly Pharmaceutical Group Co Ltd (600535) — Financial Flexibility Index
Tasly Pharmaceutical Group Co Ltd (600535) has a Financial Flexibility Index of 0.24x as of December 2025. Free cash flow of CN¥669.91 Million (operating CF CN¥552.13 Million minus capex CN¥117.78 Million) represents 0% of total liabilities (CN¥2.79 Billion). Check Tasly Pharmaceutical Group Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Tasly Pharmaceutical Group Co Ltd Financial Flexibility Index (2001–2025)
Historical Financial Flexibility Index trend for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. See 600535 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year free cash flow to debt coverage for Tasly Pharmaceutical Group Co Ltd. For the full company profile including market capitalisation, see market value of Tasly Pharmaceutical Group Co Ltd.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.65x | CN¥1.81 Billion | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -28.2% |
| 2024 | 0.90x | CN¥2.58 Billion | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +11.7% |
| 2023 | 0.81x | CN¥3.24 Billion | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +13.9% |
| 2022 | 0.71x | CN¥2.69 Billion | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -32.3% |
| 2021 | 1.04x | CN¥3.37 Billion | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +95.2% |
| 2020 | 0.54x | CN¥2.20 Billion | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +169.8% |
| 2019 | 0.20x | CN¥2.41 Billion | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +21.9% |
| 2018 | 0.16x | CN¥2.27 Billion | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +757.5% |
| 2017 | -0.02x | CN¥-310.99 Million | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -113.2% |
| 2016 | 0.19x | CN¥1.68 Billion | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +34.5% |
| 2015 | 0.14x | CN¥1.08 Billion | CN¥340.00 Million | CN¥7.71 Billion | ▼ -19.9% |
| 2014 | 0.17x | CN¥1.37 Billion | CN¥616.76 Million | CN¥7.85 Billion | ▲ +5.0% |
| 2013 | 0.17x | CN¥1.01 Billion | CN¥346.17 Million | CN¥6.07 Billion | ▼ -32.1% |
| 2012 | 0.24x | CN¥803.33 Million | CN¥413.31 Million | CN¥3.28 Billion | ▲ +25.5% |
| 2011 | 0.20x | CN¥557.71 Million | CN¥135.14 Million | CN¥2.86 Billion | ▼ -29.5% |
| 2010 | 0.28x | CN¥561.18 Million | CN¥395.05 Million | CN¥2.03 Billion | ▼ -0.8% |
| 2009 | 0.28x | CN¥517.19 Million | CN¥400.39 Million | CN¥1.85 Billion | ▲ +0.9% |
| 2008 | 0.28x | CN¥374.72 Million | CN¥260.21 Million | CN¥1.36 Billion | ▼ -26.8% |
| 2007 | 0.38x | CN¥422.78 Million | CN¥221.55 Million | CN¥1.12 Billion | ▲ +46.8% |
| 2006 | 0.26x | CN¥395.97 Million | CN¥140.56 Million | CN¥1.54 Billion | ▼ -40.2% |
| 2005 | 0.43x | CN¥511.22 Million | CN¥214.90 Million | CN¥1.19 Billion | ▼ -38.0% |
| 2004 | 0.69x | CN¥572.88 Million | CN¥203.27 Million | CN¥826.42 Million | ▲ +2.9% |
| 2003 | 0.67x | CN¥387.74 Million | CN¥59.00 Million | CN¥575.74 Million | ▼ -48.6% |
| 2002 | 1.31x | CN¥332.31 Million | CN¥206.22 Million | CN¥253.70 Million | ▲ +124.5% |
| 2001 | 0.58x | CN¥203.12 Million | CN¥83.77 Million | CN¥348.19 Million | — |